skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

12 Total results for product and free and sample content found

RxScorecard

Market Access Article Pack: Value Frameworks

28 Nov 2016

When it comes to value frameworks, one thing is certain, they’re here to stay.

Topics Reimbursement Deal trends

RxScorecard

Maximize your drugs market potential in a payer dominated world

23 Nov 2016

See how the value of drugs differentiate therapies by sub-population. Find out where the disproportionate value of your drug lies alongside competitors. Uncover demonstrable differentiated value when entering a crowded market. Discover the power of RxScorecard™.

Topics Reimbursement

RxScorecard

Examine How Payers Make Reimbursement Decisions

By Roger Longman 21 Nov 2016

Topics Reimbursement

Pink Sheet

Trump’s ACA Repeal: What’s In It For Biopharma?

By cathy-kelly 15 Nov 2016

Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.

Topics US election Reimbursement

Pink Sheet

Trump’s ACA Repeal: What’s In It For Biopharma?

By cathy-kelly 15 Nov 2016

Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.

Topics US election Reimbursement

Pink Sheet

Trump’s ACA Repeal: What’s In It For Biopharma?

By cathy-kelly 15 Nov 2016

Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.

Topics US election Reimbursement

RxScorecard

Market Access Article Pack: Indication-Based Pricing

14 Nov 2016

Indication-based pricing isn’t just coming. It’s here.

Topics Reimbursement

Datamonitor Healthcare

Inside the payer perspective market

08 Nov 2016

Topics Reimbursement

In Vivo

US Outcomes-Based Contracts: Big Uptick In Interest, But Not Execution

By cathy-kelly 06 Nov 2016

The promise of outcomes-based contracts for biopharmaceuticals has yet to be realized in the US. Although precise numbers are hard to come by, payers and manufacturers agree the field is still nascent. However, they don’t seem to be giving up on the idea.

Topics Reimbursement

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:
Pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: